total revenue vs non-gaap ep vs ahead
consensu guidanc product sale less line
investor expect gilead remain hope hcv busi begin stabil
around continu believ gilead under-valued cash flow
price target remain
gilead releas financi provid guidanc world-wide hiv sale
q/q y/i consensu hcv
sale q/q y/i also consensu
total revenu q/q y/i vs estim consensu
gilead report non-gaap gross margin vs non-gaap
sg expens revenu revenu vs
respect non-gaap ep q/q y/i
consensu
gilead guid total product sale includ hcv
revenu guid non-gaap gross margin expens
sg expens effect tax rate sens
convers investor guidanc less line recent
expect adjust estim consist notabl hcv
estim decreas product sale estim
estim tax rate project non-gaap ep
dcf-base price target remain
hcv price market share expect stabil
 hcv revenu q/q y/i ex-u hcv revenu
q/q y/i impact price compress share eros due
launch mavyret gilead hope hcv revenu begin stabil around
 payer contract place januari gilead suggest
price stabil week gt regimen though captur share
manag hope share reach equilibrium around mid-year
hcv regimen clinic develop last major disrupt market
forseeabl futur manag also note declin patient treatment
volum becom consist declin per month therefor manag
optimist hcv becom stabl predict busi
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t
oncolog platform kite expect combin launch
new taf-bas combin pill hiv market growth share gain price increas
hiv franchis sale grow compound-annual-growth-rate despit viread
patent expir gilead hcv franchis struggl declin patient volum
new competit erod sale project gilead hcv franchis gener
world-wide sale declin expect partial off-set pipelin
program includ yescarta filgotinib base dcf analysi gilead stock
under-valued expect cash flow
b/f/taf approv
phase data switch triumeq b/
interim futil analysi filgotinib phase
uc
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv fungal infect
acquir car-t oncolog platform kite gilead antivir portfolio biggest
revenu driver hcv franchis led sofosbuvir nucleosid inhibitor result
phase trial sofosbuvir-bas regimen shown potent well
toler high barrier viral resist expect hcv franchis maintain
revenu gilead lead hiv franchis anchor
tenofovir well-toler efficaci nucleotid analog gilead develop
genvoya odefsey descovi togeth captur share treatment-
naiv hiv patient drive hiv franchis revenu project
revenu
hiv sale q/q y/i consensu
launch taf-bas pill continu grow hiv franchis
gilead report taf-bas regimen account gilead hiv prescript
volum start
bictegravir pdufa date come monday februari eu decis expect
anticip fda approv next week nda well-support four
posit phase studi think b/f/taf help reclaim share hiv
market consult suggest base b/f/taf phase data becom
clear first choic regimen hiv estim increas
y/i anticip b/f/taf launch help hiv revenu grow despit
launch viread gener earlier year
gilead record yescarta revenu follow fda approv
gilead continu suggest yescarta ramp gradual center
train reimburs access secur cancer center author
treat patient gilead anticip center treat yescarta-elig
patient patient approv gilead expect payor
mostli commerci initi rest come medicar lesser
extent medicaid first year medicar drg expect grow third
payer mix approv yescarta eu continu anticip
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin initi pivot
phase ii yescarta r/r indol nhl initi addit
gilead expect complet pivot ph ii construct yescarta
differ manufactur mcl initi pivot phase ii
adult pediatr
gilead also highlight recent progress pipelin develop inflamm five
phase studi filgotinib on-going rheumatoid arthriti ulcer coliti
crohn diseas finch ra fulli enrol data anticip
also ra expect complet enrol respect
phase ii studi filgotinib inflammatori diseas also on-going
data expect later year decemb gilead file ind intern
develop small molecul inflammatori condit clinic develop expect
begin come month
selonsertib stellar phase trial nash recent complet enrol
enrol stellar phase expect complet result
anticip gilead conduct phase ii combin studi selonsertib
inhibitor fxr agonist patient nash initi data
combin studi present european associ studi
liver annual meet april larger phase ii combin studi selonsertib/
anticip begin
oncolog phase ii studi andecaliximab combin momelotinib gastric
cancer complet quarter data present futur medic confer
gilead develop market treatment hiv hbv hcv fungal infect
gilead antivir portfolio largest revenu driver next sever
year gilead lead hiv franchis anchor tenofovir well-toler
gener revenu captur share patient newli initi
hiv therapi tenofovir disoproxil fumar viread lost patent
protect gilead develop second gener version tenofovir
alafenamid taf improv safeti extend patent protect
project sale gilead hiv franchis grow
launch new patent-protect combin pill b/c/f/taf stribild
genvoya e/c/f/taf descovi f/taf odefsey e/r/taf taf
regimen extend commerci life franchis gilead hcv franchis built
around sovaldi nucleosid inhibitor whose potenc high barrier resist
made cornerston market-lead all-or hcv combin
sovaldi launch decemb eu januari
approv gilead harvoni sofosbuvir ledispavir octob
brought first fda-approv interferon free regimen genotyp hcv
patient largest hcv popul hcv franchis got fast
start post revenu unfortun best day
gilead hcv franchis past emerg competit gild hcv
franchis gener revenu estim continu
declin gilead recent expand oncolog franchis
acquisit kite gilead gain yescarta car-t therapi
anhl approv fda octob well lead car-t
platform cowen project yescarta achiev revenu third line
anhl hope gilead trough earn final
sight two year rapid declin hcv revenu project non-gaap
ep non-gaap ep grow compound-annual-growth-rate gilead
current trade forward pe project cash flow yield
base dcf analysi gilead stock under-valued expect
potenti fda approv b/f/taf
phase data triumeq b/f/taf switch trial
complet phase ii studi andecaliximab nivolumab gastric cancer
initi phase trial hiv capsid inhibitor
possibl eu approv yescarta aggress nhl
initi pivot phase ii yescarta r/r indol nhl zuma
initi pivot phase ii adult zuma
complet enrol filgotinib finch studi ra
primari endpoint analysi phase ii data psc
complet phase ii filgotinib psoriat arthriti
initi phase ii studi nunuc
interim analysi phase trial filgotinib ulcer coliti
complet enrol phase studi selonsertib nash stellar
initi phase ii
complet enrol filgotinib finch studi ra
potenti eu approv b/f/taf
complet phase ii ebola
complet phase ii studi filgotinib ankylos spondyl
phase ii data tirabrutinib idelalisib entospletinib r/r cll
complet ph ia mage solid tumor
file ind tcr target solid tumor
achiev endpoint tirabrutinib phase ii combin studi r/r cll
result filgotinib finch studi ra
complet pivot phase ii mcl zuma
initi pivot phase ii ped zuma
initi phase cll zuma
complet ph ia studi anti-bcma mm
potenti chines launch sovaldi harvoni
phase ii data cutan lupu erythematosu
complet phase trial descovi prep
complet enrol filgotinib divers studi crohn diseas
complet phase studi hiv cure
data phase ii sjogern syndrom
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest net income/ loss incom loss attribut non-controlling net fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
